Therapeutic area intelligence for Geographic Atrophy with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Roche →

Assets

No related entities indexed yet.

Recent signals(1)

ClinicalJuly 25, 2026

Genentech's OpRegen Study Targets Geographic Atrophy in AMD with Subretinal Delivery

Genentech is conducting a study to evaluate the safety and activity of OpRegen delivered via subretinal surgery in patients with geographic atrophy secondary to AMD.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.